Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Skf 107457
- Development stage
- Preclinical
- Modality
- Small Molecules, Peptides
01
Overview
Skf 107457 is an experimental small molecule HIV protease type 1 inhibitor. It is a hexapeptide substrate analog in which the scissile bond has been replaced by a hydroxyethylene isostere, making it resistant to enzymatic cleavage and allowing it to inhibit the activity of HIV protease. This mechanism blocks viral polyprotein processing, thereby interfering with viral maturation and replication. The compound has not been approved for clinical use and remains primarily a research tool in AIDS/HIV studies[1][2][3][4].
- Other names
- Ala-Ala-Phepsi(CH(OH)CH2)Gly-Val-Val-OCH3DB04191DB-04191DB 04191DTXSID80155143DTXSID-80155143DTXSID 80155143HY-120880HY120880HY 120880CS-0079462CS0079462CS 0079462NS00069602NS-00069602NS 00069602
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on Skf 107457.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skf 107457.